Judge Orders Weight Loss Drug Lawsuit to Arbitration
A Los Angeles patient must take her coverage dispute with Anthem Blue Cross to arbitration following a court ruling.
Updated on Oct. 20, 2026 in Weight Loss
Live Poll
Should insurance companies continue covering weight-loss medication after a patient reaches a healthy weight?
A Los Angeles Superior Court judge has ordered a lawsuit against Anthem Blue Cross over a weight-loss drug coverage denial into private arbitration. The case highlights ongoing disputes regarding insurance criteria for medications like Zepbound for patients whose weight has dropped below initial eligibility thresholds.
Why it matters
This case underscores the complexities patients face when navigating health plan coverage for chronic weight management, especially when insurance eligibility criteria for medications shift as a patient reaches weight-loss goals. It brings into focus the challenges of maintaining access to weight-loss treatments under evolving HMO plan policies.
A legal ruling by the Los Angeles Superior Court has moved a breach of contract claim to private arbitration, involving a dispute over a BMI threshold of 40. Whether the insurance denial qualifies as a breach of contract remains unresolved pending the arbitration outcome.
The players
Anthem Blue Cross
A health insurance provider offering various HMO and PPO plans in California.
Colin Leis
A Los Angeles Superior Court judge who ordered the current case into arbitration.
Alicia Butterfield
The plaintiff who sued an insurance provider over a denied weight-loss drug claim.
The details
The dispute centers on the clinical criteria Anthem Blue Cross requires for coverage of Zepbound, specifically the requirement that the patient meet a morbid obesity threshold. The plaintiff alleges the insurer rejected the claim after her weight loss caused her to drop below the threshold that previously qualified her for treatment. Because the court determined that state arbitration disclosure requirements do not apply to these Covered California plans, the case will proceed through private arbitration rather than a jury trial.
Timeline
2022: Blue Shield approved coverage for Mounjaro.
February 2025: The plaintiff enrolled in an Anthem HMO plan.
April 2025: Anthem denied the coverage request for Zepbound.
July 2025: The lawsuit was filed in the Los Angeles Superior Court.
April 19, 2027: A status conference for the case is scheduled.
Health Landscape
This case sits at the intersection of state-mandated arbitration disclosures and the specific governance of Covered California insurance plans. The ruling clarifies the legal framework governing disputes over medical coverage denials under these specific regulatory environments.
If you are managing your weight with medication, it is important to review your specific plan document's criteria for ongoing coverage if your weight drops below the initial qualification threshold. Discuss any concerns about potential coverage gaps with your physician or a patient advocate.
The takeaway
Insurance coverage for weight-loss medications may depend on maintaining specific clinical indicators, which can complicate long-term treatment access. Patients concerned about coverage continuity should request written clarity on renewal requirements from their insurer.
What happens next
A status conference for the case is scheduled for April 19, 2027.
Further reading
Learn more about navigating insurance hurdles for chronic weight management in our Weight Loss section.
Source note: This article includes information reported by My News LA.
Live Poll
Should insurance companies continue covering weight-loss medication after a patient reaches a healthy weight?
